Corcept Therapeutics Incorporated CORT

CORT Company Overview

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on the discovery, development, and commercialization of medicines that modulate the effects of cortisol. The company operates primarily within the biotechnology and pharmaceutical industries, with a specialization in endocrine and metabolic disorders. Its business model centers on developing proprietary cortisol modulators to address diseases driven or exacerbated by excess cortisol activity.

The company’s primary revenue driver is Korlym, an oral glucocorticoid receptor antagonist approved for the treatment of hyperglycemia secondary to endogenous Cushing’s syndrome in adult patients with type 2 diabetes mellitus or glucose intolerance who are not candidates for surgery or have had unsuccessful surgery. Corcept has positioned itself uniquely by focusing exclusively on cortisol modulation, an area with limited direct competition. Founded in 1998, the company evolved from a research-focused enterprise into a commercial-stage pharmaceutical company following the U.S. approval of Korlym in 2012.